Labiotech.eu’s Post

It’s time to find out who bagged the biggest private biotech investments in June 2024! 💰 The biggest funding rounds went to the companies Formation Bio, ITM Isotope Technologies Munich SE, and Marea Therapeutics. 📈 Meanwhile, around the world, oncology and central nervous system players attracted the biggest funding rounds overall. 🌍 Read our latest article to find out more about biotech’s biggest private investments in June, as we break down the investments by location and funding type, and compare June’s fundraising to previous months. 💡 https://lnkd.in/dYvuBVt9 #biotechinvestments #oncologyresearch #biotechfunding #healthcareinnovation #investmenttrends #globalbiotech #lifesciences Santa Ana Bio, Inc. | Alzheon, Inc. | Preserving Future Memories | Bright Peak Therapeutics | iOnctura | InduPro | Exsilio Therapeutics | Elion Therapeutics | Enveda Biosciences | Iambic Therapeutics | Spur Therapeutics | āshibio, Inc | Adcytherix | Envisagenics | Vilya | Frontier Medicines | Augustine Therapeutics | GPN Vaccines

10 Noteworthy Global Biotech Companies that Got Funded in the first Quarter of 2024 According to data sourced from Crunchbase, the funding for Biotech companies represents a 161 percent upsurge compared to the USD 1.1 billion raised by the largest funding rounds which involved healthcare-focused biotech companies in the first quarter of 2023. Read the full article: https://goo.su/HCqWR By Samrat Pradhan, Managing Editor, #FinanceOutlookIndia Zephyr AI Yiyuan Yin FogPharma Mike Nolan Andrew Chi Baiteng Zhao Tubulis GmbH Laura Shawver Rakuten Medical Clasp Therapeutics Greg Chow, Freenome Diagonal Therapeutics Jixing Pharmaceuticals Obsidian Therapeutics Alamar Biosciences, Inc. ARS Pharmaceuticals, Inc. Nadia Agopyan, Ph.D., RAC Mark M, Sionna Therapeutics BlossomHill Therapeutics, Inc. BJ Sullivan, PhD, BioAge Labs Catherine Priest, Neurona Therapeutics #GlobalBiotech #FirstQuarter2024 #Biotechnologyindustry #FundingRounds #EmergingBiotechFirms #VentureCapital #TechnologicalAdvances #InnovationSpotlight

Drug Discovery Services Market Latest Statistics 2024 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭: https://lnkd.in/dtcN7Umn The size of global drug discovery services market in terms of revenue was estimated to be worth $20.6 billion in 2023 and is poised to reach $41.3 billion by 2028, growing at a CAGR of 14.9% from 2023 to 2028 Companies From the Market HotSpot Therapeutics, Inc.   NanoImaging Services   Hamilton Storage Sartorius Jubilant Biosys Limited BioXcel, LLC Evotec NuChem Sciences - Sygnature Discovery North America  Enko® abcam BenevolentAI Exscientia Eurofins Advinus  Selleck Chemicals LLC     CNIO - Spanish National Cancer Research Centre      CENTOGENE   Premas Biotech Ridgeline Discovery Biotage Isomorphic Labs Xaira Therapeutics  Pioneering Medicines  JSS Medical Research SPT Labtech Selvita TandemAI bit.bio Enable Medicine Ontario Institute for Cancer Research      Healx   Experimental Drug Development Centre (EDDC) Gubra Xenon Pharmaceuticals Inc. Aurigene Oncology Limited   OSE Immunotherapeutics      Enterome Ncardia IRBM Nanolive SA  AQEMIA 

🚀 Funding Frenzy in Biopharma: 2023 OrbiMed Funding Dashboard Insights by Octavus Consulting The 2023 OrbiMed Funding Dashboard paints an exciting picture of the pharmaceutical and biotechnology funding landscape. Let's dive into the key highlights: 💰 $3.08B* Total Funding Across 38 Deals 💠 Largest funding rounds: Series B ($724M), Series A ($639.6M), Series C ($529M) 🏆 Top 3 Largest Fundings: 💠Caris Life Sciences Inc. ($400M) 💠Upstream Biosciences ($200M) 💠ADARx Pharmaceuticals Inc. ($200M) 🌍 Global Reach: Majority of Investments in the US 🗽(25 companies), followed by China, Israel, and other countries 🔬 Investment Focus Areas: Oncology, Neurology, Hematology, Infectious Disease 🧬 Stage of Investment: 👉 Platform & Own Product Development (15 companies) 👉 Early R&D (11 companies) 👉 Late Stage Development & Commercialization (6 companies) 👉 Rare/Orphan Specialization (4 companies) 1 🔑 Key Takeaways: ▶ Biopharma funding remains robust, with significant investments in cutting-edge therapies and platform technologies ▶Global investors are actively seeking opportunities across the healthcare innovation ecosystem ▶Oncology, neurology, and infectious diseases continue to attract substantial funding Feel free to reach us at bd@octavusconsulting.com for any bespoke funding and data analysis #BiopharmaFunding #HealthcareInnovation #VentureCapital #MedicalResearch #Biotech #Pharma

📰 Great news! Bright Peak Therapeutics has successfully secured investment of 90 million US dollars after closing a Series C financing round. According to a press release, Johnson & Johnson Innovation – JJDC led the financing round for the biotechnology company, which is based at our Switzerland Innovation Park Basel Area - Main Campus and in San Diego, in the US State of California. With the proceeds from this financing round, the company is aiming to advance BPT567, a first-in-class PD1-IL18 immunoconjugate, into a Phase 1/2a clinical trial in the second half of 2024. Preclinical models have demonstrated that single agent BPT567 possesses a highly targeted biological and therapeutic effect with potent antitumor activity by blocking the PD-1 receptor, while at the same time directing the potent pro-inflammatory effects of IL-18 specifically to effector T cells in the tumor microenvironment. Read more right here: https://lnkd.in/ecmJkkAv 💬 “We are now well positioned to bring much needed innovation to the field of anti-PD-1 immune-checkpoint inhibition and look forward to advancing our lead program into the clinic later this year across multiple tumor types”, comments Fred Wiklund, Chief Executive Officer of Bright Peak, in the press release, before adding: “This capital raise provides financial flexibility to bring new therapeutic modalities to patients with cancer and we’re delighted to have attracted the confidence of a global pharmaceutical company and strong support from such a distinguished syndicate of leading life sciences investors”. 👉 Meet our residents right here: https://lnkd.in/eSKdb6SD senn.com #innovation #lifesciences #success #biotech

Drug Discovery Services Market Worth $41.3 billion by 2028 🔵𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐑𝐄𝐄 𝐒𝐚𝐦𝐩𝐥𝐞:https://lnkd.in/diXdYs_N The global drug discovery services market in terms of revenue was estimated to be worth $20.6 billion in 2023 and is poised to reach $41.3 billion by 2028, growing at a CAGR of 14.9% from 2023 to 2028. 🔵 𝐌𝐚𝐢𝐧 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬: X-Chem, Inc. Quantori NanoCellect Biomedical, Inc.      FUJIFILM Cellular Dynamics, Inc    Iambic Therapeutics  Sygnature Discovery XtalPi Inc. Skyhawk Therapeutics    BPS Bioscience Inc.     Biocytogen  Anima Biotech   The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology Active Motif Reaction Biology Kallyope NETZSCH Premier Technologies, LLC       o2h discovery      Structure Therapeutics     Terray Therapeutics Remix Therapeutics       Eureka Therapeutics, Inc    Neomorph, Inc.      Charnwood Discovery   ACEA Biosciences  Plexium   AnaSpec Eurofins DiscoverX HTG Molecular Diagnostics       Calibr-Skaggs Institute for Innovative Medicines        MBL International Corporation     GemPharmatech Belharra Therapeutics HotSpot Therapeutics, Inc.   Neuron23       Jubilant Biosys Limited        Cajal Neuroscience NanoImaging Services  Skills Alliance abcam BenevolentAI 

We’re delighted to announce that our wholly-owned subsidiary, Nona Biosciences, has entered into a global license agreement with Pfizer for the global clinical development and commercialization of Nona’s MSLN-targeted antibody-drug conjugate (ADC), HBM9033. This agreement represents a significant milestone in the advancement of our proprietary Harbour Mice® platform and in the innovative field of ADC technology, affirming Nona’s robust capabilities and expertise in antibody discovery and development. The fully human monoclonal antibody (mAb) in HBM9033 is derived from the Harbour Mice® platform and possesses well-tuned properties, exhibiting reduced binding to shedding MSLN (sMSLN) while maintaining strong binding and internalization to membrane-bound MSLN. The unique design of the mAb ensures superior potency and safety in various preclinical tumor models with differing MSLN expression levels, positioning HBM9033 as a potential globally best-in-class therapeutic option. This partnership with Pfizer expands our global network of collaborations, reinforcing our commitment to providing cutting-edge technology innovations in therapeutics development and, ultimately, bringing meaningful benefits to patients worldwide. Learn More: https://lnkd.in/eNXhwbT2 #biotechnology #innovation #global #company #antibodydiscovery #technology #therapeutics #antibody #biotech #development

TLDR Biotech for June 26 - 27 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭: Novo Nordisk buys 2seventy bio’s Hemophilia A asset for $40M 🤝 + 1 more story 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐓𝐫𝐢𝐚𝐥𝐬: Silence Therapeutics reports encouraging early Ph1 blood disorder data 🩸 + 2 more stories 𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐋𝐚𝐮𝐧𝐜𝐡𝐞𝐬: WayPoint Bio launches to "test hundreds [of cell therapies] at once" 🤯 𝐅𝐮𝐧𝐝𝐫𝐚𝐢𝐬𝐞𝐬: Holoclara’s worm-derived therapies raise a $16M Series A 🪱 + 5 more stories 𝐈𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭𝐬: Vigil Therapeutics receive $40M strategic investment from Sanofi 💼 𝐌𝐞𝐫𝐠𝐞𝐫𝐬 & 𝐀𝐜𝐪𝐮𝐢𝐬𝐢𝐭𝐢𝐨𝐧𝐬: AbbVie brings the heat, buys Celsius Therapeutics for $250M cash 🔥 + 3 more stories 𝐏𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩𝐬: Kite Pharma signs on to assess Cellares’ cell therapy manufacturing platform 🤖 𝐏𝐨𝐥𝐢𝐭𝐢𝐜𝐬 & 𝐏𝐨𝐥𝐢𝐜𝐲: Medicare inches closer to covering weight loss drugs 💊 𝐏𝐫𝐨𝐝𝐮𝐜𝐭 𝐋𝐚𝐮𝐧𝐜𝐡𝐞𝐬: Eisai, Biogen's Leqembi launches in China 🚀 All this and more in today's TLDR Biotech newsletter - link to the latest issue: https://lnkd.in/gfw7pkVK Or subscribe to get it straight to your inbox: https://lnkd.in/gh68uhTQ #tldrbiotech #biotechnews #pharmanews

Drug Discovery Market Set for Rapid Growth: $41.3 Billion by 2028 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞: https://lnkd.in/dkur5VbB The global #drugdiscovery services market is on a rapid growth trajectory, estimated to reach an impressive $41.3 billion by 2028! 🎉 This significant growth, at a CAGR of 14.9% from 2023 to 2028, demonstrates the increasing demand for advanced drug discovery services. X-Chem, Inc. Quantori NanoCellect Biomedical, Inc. FUJIFILM Cellular Dynamics, Inc. Iambic Therapeutics Sygnature Discovery XtalPi Inc. Skyhawk Therapeutics BPS Bioscience Inc. Biocytogen Anima Biotech The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology Active Motif Reaction Biology Kallyope NETZSCH Premier Technologies, LLC o2h discovery Structure Therapeutics Terray Therapeutics Remix Therapeutics Eureka Therapeutics, Inc. Neomorph, Inc. Charnwood Discovery ACEA Biosciences Plexium AnaSpec Eurofins DiscoverX HTG Molecular Diagnostics Calibr-Skaggs Institute for Innovative Medicines MBL International Corporation GemPharmatech Belharra Therapeutics HotSpot Therapeutics, Inc. Neuron23 Jubilant Biosys Limited Cajal Neuroscience NanoImaging Services Skills Alliance abcam BenevolentAI